Please provide your email address to receive an email when new articles are posted on . The authors reported that both propensity score matching and propensity score weighting distinguish between the ...
A phase II trial combining SHR-1316, bevacizumab, and cisplatin/carboplatin in patients with TNBC with active brain metastases. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
SAN DIEGO -- In a propensity-matched comparison of two CAR T-cell therapies, ciltacabtagene autoleucel (cilta-cel, Carvykti) demonstrated better efficacy than idecabtagene vicleucel (ide-cel, Abecma) ...
Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors Using linked administrative databases, we created a retrospective cohort ...
Saurav Narayan Nanda et al conducted a study to compare functional and radiographic outcomes between medial opening-wedge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results